After multiplying inside a host cell, the string-like Ebola virus is emerging to infect more cells. Credit: Heinz Feldmann, Peter Jahrling, Elizabeth Fischer and Anita Mora, National Institute of Allergy and Infectious Diseases, National Institutes of Health.

Results from a Phase I clinical trial have shown the investigational mAb114 solution to be safe in the treatment of Ebola.

The trial was launched in May last year at the National Institutes of Health (NIH) Clinical Center in Bethesda, Maryland, US.

Go deeper with GlobalData

Go deeper with GlobalData

The gold standard of business intelligence.

Find out more

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

NIH unit National Institute of Allergy and Infectious Diseases (NIAID) Vaccine Research Center (VRC) conducted and sponsored the trial.

NIAID VRC’s single monoclonal antibody mAb114 was also found to be well-tolerated and easy to administer.

The Phase I trial enrolled 18 healthy adults who received a single intravenous infusion of mAb114 for around 30 minutes.

“The investigational treatment is currently being offered to Ebola patients in the DRC under compassionate use.”

Three of the subjects received a 5mg/kg dose, while five received a 25mg/kg and ten participants received a 50mg/kg dose of mAb114.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

All infusions were reported to be well-tolerated. Four participants experienced mild side effects, including discomfort, muscle or joint pain, headache, nausea, and chills in the three days after the infusion.

The results also demonstrated relatively uniform levels of absorption, distribution, and elimination of mAb114.

NIH in a statement said: “The investigational treatment is currently being offered to Ebola patients in the Democratic Republic of the Congo (DRC) under compassionate use and as part of a Phase II/III clinical trial of multiple investigational treatments.

“mAb114, a single monoclonal antibody, binds to the core receptor binding domain of the Zaire ebolavirus surface protein, preventing the virus from infecting human cells.

“Scientists isolated the antibody from a human survivor of the 1995 Ebola outbreak in Kikwit, DRC.”

NIAID VRC is also planning to begin a Phase I trial of mAb114 for the treatment of Ebola in Africa.

Clinical Trials Arena Excellence Awards - Nominations Closed

Nominations are now closed for the Clinical Trials Arena Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact

Excellence in Action
Science 37 has won the Research and Development Award in the Site Innovation category for its FDA inspected Direct-to-Patient Site model, delivering nationwide access, faster enrollment and higher retention. Explore how its virtual-first, in home approach is reshaping trial operations and accelerating time to data-driven decisions..

Discover the Impact